Skip to main content
Log in

Propranolol ameliorates thrombocytopenia in patients with cirrhosis

  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Background.

Propranolol causes splanchnic arterial vasoconstriction owing to the unopposed alpha vasoconstriction resulting from the blockade of beta-2 adrenoceptors. It is therefore hypothesized that this drug may cause vasoconstriction in the splenic arterial circulation and, thus, modify the manifestations of hypersplenism, such as thrombocytopenia. The aim of the present study was to test this hypothesis. Methods. Nineteen patients with cirrhosis and thrombocytopenia (fewer than thrombocytes 7 × 104/mm3) were include. The subjects of the study. All of them were studied in the morning after an overnight fast. To evaluate splenic arterial hemodynamics, the pulsatility index was measured by Doppler ultrasonography. Platelet counts and platelet-associated immunoglobulin G levels were also recorded. The subjects were then randomized to receive propranolol (n = 10) or placebo (n = 9). The measurements were repeated after 1 week of propranolol or placebo administration. The dose of propranolol was determined so that a 20% to 25% reduction in heart rate was achieved. Results. Placebo administration caused no significant changes in splenic artery hemodynamics. In contrast, propranolol administration significantly increased the intra splenic artery pulsatility index (from 1.10 ± 0.06 to 1.24 ± 0.08; P < 0.01). Placebo administration caused no significant changes in the platelet count. In contrast, propranolol administration significantly increased the platelet count (from 4.5 ± 0.3 to 6.1 ± 0.73 × 104/mm3; P < 0.05). Furthermore, the change in platelet count was significantly correlated with either the change in extrasplenic artery pulsatility index (r = 0.78, P < 0.05) or the change in intrasplenic artery pulsatility index (r = 0.78, P < 0.01). Platelet-associated immunoglobulin G levels were not modified in either of the two groups. Conclusions. Propranolol ameliorates thrombocytopenia in patients with cirrhosis. This effect may be caused mainly by hemodynamic changes in the spleen, rather than being caused by immunological mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: February 22, 2001 / Accepted: August 24, 2001

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sakai, K., Iwao, T., Oho, K. et al. Propranolol ameliorates thrombocytopenia in patients with cirrhosis. J Gastroenterol 37, 112–118 (2002). https://doi.org/10.1007/s005350200005

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s005350200005

Navigation